

**Supplementary information, Table S5 Comparisons of therapies administration during hospitalization in nifedipine-treated group with those in general SFTS group or non-nifedipine group.**

	Nifedipine-treated group (n=83)	General SFTS group (n=249)	Non-nifedipine group (n=48)	P <sup>a</sup>	P <sup>b</sup>
Recombinant human granulocyte colony-stimulating factor	61 (73.5)	194 (77.9)	35 (72.9)	0.409	0.943
XueBiJing*	53 (63.9)	174 (69.9)	38 (79.2)	0.307	0.067
Immunoglobulin	53 (63.9)	139 (55.8)	24 (50.0)	0.199	0.121
Ribavirin	38 (45.8)	118 (47.4)	19(39.6)	0.800	0.490
Corticosteroid	27 (32.5)	69 (27.7)	18 (37.5)	0.402	0.564
Thrombopoietin	24 (28.9)	70 (28.1)	10 (20.8)	0.888	0.309
Platelets transfusion	33 (39.8)	97 (39.0)	22 (45.8)	0.897	0.497
Plasma transfusion	37 (44.6)	86 (34.5)	16 (33.3)	0.101	0.206

\* a traditional Chinese medicine for treating sepsis;

<sup>a</sup>indicates difference between nifedipine-treated group and general SFTS group;

<sup>b</sup>indicates difference between nifedipine-treated group and non-nifedipine group.